Shopping Cart
- Remove All
Your shopping cart is currently empty
ALW-II-41-27
🥰Excellent
Catalog No. T4344Cas No. 1186206-79-0
Alias Eph receptor tyrosine kinase inhibitor
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
ALW-II-41-27
🥰Excellent
Purity: 99.52%
Catalog No. T4344Alias Eph receptor tyrosine kinase inhibitorCas No. 1186206-79-0
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $63 | In Stock | |
| 2 mg | $98 | In Stock | |
| 5 mg | $179 | In Stock | |
| 10 mg | $277 | In Stock | |
| 25 mg | $459 | In Stock | |
| 50 mg | $673 | In Stock | |
| 100 mg | $958 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $253 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "ALW-II-41-27"
Dasatinib monohydrate
Cited
BMS-354825 Monohydrate
T1448L863127-77-9
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
- $33
Size
QTY
CitedAZ12672857
T9650945396-55-4In house
AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphorylation of EphB4 in transfected CHO-K1 cells with IC50 of 9 nM.
- $64
Size
QTY
Eph inhibitor 2
Ehp-inhibitor-1
T5451861249-59-4
Eph inhibitor 2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
- $87
Size
QTY
KYL acetate(676657-00-4 free base)
TP1895L1
KYL acetate is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. Exhibits a long half life in cell culture media (8 and 12 hours in PC3 and C2C12 media respectively). Neuroprotective.
- $133
Size
QTY
Urolithin D
T74005131086-98-1
Urolithin D is a competitive and selective reversible antagonist of the EphA receptor, an ellagitannin colonic metabolite that inhibits EphA2 phosphorylation in prostate cancer cells, attenuates triglyceride accumulation in adipocytes and hepatocyte cultures, and may be used in the study of metabolic disorders.
- $55
Size
QTY
ALW-II-49-7
T677361135219-23-6
ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase, with an EC50 value of 40 nM in cell.
- $65
Size
QTY
Ehp-inhibitor-2
T5452861249-77-6
Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
- $39
Size
QTY
JI-101
JI 101, CGI-1842
T3476900573-88-8
JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4).
- $31
Size
QTY
Sitravatinib Cited
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
- $47
Size
QTY
CitedAWL-II-38.3
T385111135205-94-5
AWL-II-38.3 is a highly potent EphA3 inhibitor with potent kinase inhibitory activity against EphA3 but no significant cellular activity against Src family kinases or b-raf.
- $74
Size
QTY
Tivozanib
KRN951, AV-951
T2456475108-18-0
Tivozanib (KRN951) is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.
- $34
Size
QTY
123C4
TP15612034159-30-1
123C4 is a potent, selective, and competitive agonist of the receptor tyrosine kinase EPHA4 (Ki=0.65 μM)[1].
- $147
Size
QTY
Select Batch
Purity:99.52%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy. |
| Targets&IC50 | Eph family tyrosine kinase:11 nM |
| In vitro | ALW-II-41-27 inhibits Ba/F3 cells (EC50<500 nM) transformed with Tel fusions of Kit, EphA3, Fms, KDR, FLT1, FGR, Src, Bmx, Lyn, and Bcr-Abl, and shows cross-reactivity with Bcr-Abl. Additionally, ALW-II-41-27 inhibits b-Raf, CSF1R, DDR1, DDR2, EphA2, EphA8, EphB1, EphB2, Kit, EphB3, Frk, Lck, EphA5, p38α, p38β, PDGFRβ, PDGFRα, and Raf1. |
| Alias | Eph receptor tyrosine kinase inhibitor |
| Molecular Weight | 607.69 |
| Formula | C32H32F3N5O2S |
| Cas No. | 1186206-79-0 |
| Smiles | CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cncc(c4)-c4cccs4)c3)cc2C(F)(F)F)CC1 |
| Relative Density. | 1.321 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (90.51 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ALW-II-41-27 | purchase ALW-II-41-27 | ALW-II-41-27 cost | order ALW-II-41-27 | ALW-II-41-27 chemical structure | ALW-II-41-27 in vitro | ALW-II-41-27 formula | ALW-II-41-27 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.